LGC LAUNCHES ADME-TOX SCREENING SERVICE FOR PHARMACEUTICAL, DRUG DISCOVERY & COMBINATORIAL SECTOR

Main Menu | News By Date | News By Supplier | News By Category | About Us

LGC LAUNCHES ADME-TOX SCREENING SERVICE FOR PHARMACEUTICAL, DRUG DISCOVERY & COMBINATORIAL SECTOR
18 February 2003 - LGC

LGC, the UK´s leading independent analytical laboratory, is expanding its bioanalytical services for pharmaceutical and drug discovery companies with the introduction of in vitro Absorption, Distribution, Metabolism, Excretion, Toxicology screening in new facilities at Teddington. LGC´s new range of ADME-Tox screening services, which together are able to filter out library compounds with poor pharmacokinetic profiles, include Caco-2 permeability, in vitro metabolism, plasma stability, cellular toxicology and plasma protein binding.

Dr John Marriott, Director of Analytical Technology at LGC and Government Chemist, said: "In vitro ADME-Tox screening is now an integral part of the pharmaceutical industry´s overall strategy to reduce the attrition rate in bringing drugs to market - the ´fail early, fail cheaply´ paradigm. LGC is working with pharmaceutical companies looking to outsource services to achieve the best cost-effectiveness, and discovery and combinatorial companies wanting to have their lead compounds screened."

ADME-Tox screening is the latest in a series of services LGC now supplies to the pharmaceutical sector. Companies have the option to integrate the new service with others already established, from proteomic and genomic analyses, to tandem LC-MS-MS method development and validation, and have access to LGC´s Runcorn facility, which is equipped with specialist instrumentation to support a variety of pharmaceutical applications.

Niall Martin, Head of Drug Discovery at KuDOS Pharmaceuticals Limited, said: "We have used LGC´s ADME-Tox service and are extremely happy with the quality and speed of the work. As a small pharmaceutical company, it´s important that we have flexibility in the models and LGC have proven excellent in generating the results we need for our drug discovery programmes."

Dr Richard Worswick, LGC´s Chief Executive, said: "At LGC, we are committed to good bioanalytical practice to improve analytical data and results for the pharmaceutical industry. One project we lead under the DTI's Measurements for Biotechnology programme is to enable in vitro hepatocyte-based measurements for drug metabolism and hepatoxicity to be compared. We hold exclusive commercialisation rights to the patented diagnosis of the CYP2D6 'poor metaboliser' gene variation and, trading as LGC Promochem, we supply pharmaceutical, clinical, biomaterial and other reference substances across Europe."

KuDOS Pharmaceuticals is a leader in the discovery and development of novel small molecule drugs that target DNA repair enzymes and signalling pathways for the treatment of human diseases, in particular cancer.

http://www.lgc.co.uk

About: LGC
LGC is Europe's leading independent analytical laboratory providing advanced chemical, biochemical and forensic analysis, diagnostic services, DNA testing and genetic screening, research, method development, consultancy, training and analytical outsourcing. LGC operates in a diverse range of markets, in both the public and private sectors, including foods, pharmaceuticals, biotechnology, environment and chemicals and is the national measurement laboratory for chemical and biochemical analysis. LGC's services are designed to help organisations produce high quality data on which to base scientific and commercial decisions. Reference materials supplied by our market-leading distribution business, LGC Promochem, underpin the quality of measurement in many industrial sectors including pharmaceuticals. LGC Promochem distributes reference standards and ATCC biomaterials throughout Europe and in India. Growing at around 15% per annum and majority-owned by Legal & General Ventures since April 2004, LGC is based in Teddington, Middlesex, with additional laboratory facilities in Runcorn, Cheshire, in Edinburgh, Scotland and in Luckenwalde, Germany. Further offices are located in France, Germany, Italy, Poland, Spain, Sweden and India.

More News:
  • For February 2003
  • From LGC
  • For Analytical Services